USPTO serial 79224919
ISKRA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- AVENT, TEAGUE A
- Law office
- TMO LAW OFFICE 126
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with ISKRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for the treatment of psychoorganic syndrome, neuropsychiatrie and psychiatric diseases, nervous system disorders, Alzheimer disease, parkinson disease, vertigo of different origin, cardiovascular diseases, stroke, cerebrovascular stroke, vegetative-vascular dystonia, neurodegenerative diseases, neuroinfections, somatoform autonomic dysfunction, atherosclerosis, attention deficit disorder, diseases followed by abnormal changes in bioelectrical characteristics of the brain, congestive heart failure, hyperpiesis, neuroticism, psychosomatic disease, stress disorders, asthenic syndrome, neurotoxicosis and obesity; pharmaceutical and veterinary preparations for use in the prevention of parasitic infections, inflammation and inflammatory diseases, respiratory and infectious diseases, immunological, fungal infections, viral infections, parainfluenza, adenovirus, respiratory syncytial virus, coronavirus, labially herpes, genital herpes, chicken pox, herpes zoster, infectious mononucleosis, intestinal infections of viral etiology, including calicivirus, adenovirus, coronavirus, rotavirus, enteroviruses, enteroviral and meningococcal meningitis, hemorrhagic fever with renal syndrome, tick-borne encephalitis, bacterial infections, pseudotuberculosis, whooping cough, yersiniosis, pneumonia; pharmaceutical and veterinary preparations for use in the prevention of bacterial complications of viral infections, prevention of super bacterial infection; pharmaceutical preparations, namely, antihistamines; pharmaceutical preparations for the treatment of AIDS/HIV infection; pharmaceutical preparations, namely, psychotropics; pharmaceutical preparations for the treatment of erectile dysfunction, benign prostatic hyperplasia, prostatitis, dysuric disorders, autonomic disturbances of menopause; pharmaceutical preparations for improving digestion and reducing flatulence; pharmaceutical preparations for the treatment of irritable bowel syndrome, functional gastrointestinal disorders; pharmaceutical preparations, namely, anticonvulsants; pharmaceutical preparations, namely, antianxiety preparations; pharmaceutical preparations, namely, cough treatment preparations; pharmaceutical preparations, namely, preparations for the treatment of respiratory tract infection; pharmaceutical preparations for the treatment of rheumatic arthritis, osteoarthrosis, arthropathy, nonspecific ulcerative colitis; pharmaceutical antihypoxic preparations for use in the treatment of respiratory, pulmonary and circulatory diseases; pharmaceutical and veterinary preparations, namely, antioxidants; pharmaceutical nootropic preparations for use in the improvement of cognitive functions, for use in the treatment of memory diseases and disorders; pharmaceutical vasoprotective preparations for use in the treatment of blood disorders, hemorrhoids, varicose veins and vascular diseases; pharmaceutical antihyperglycemic preparations for use in the treatment of elevated levels of glucose in the blood and elevated levels of glycated hemoglobin in the blood; pharmaceutical preparations for the treatment of alcohol and nicotine addiction; homeopathic supplements; food for babies; dietary supplements for humans and animals; capsules sold empty for medicines; cachets for pharmaceutical purposes, namely, flat capsules sold empty for enclosing unpleasant-tasting pharmaceuticals; appetite suppressant pills | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 27, 2019 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 9, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 7, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 28, 2019 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 12, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 12, 2019 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 7, 2018 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Sep 7, 2018 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 16, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 1, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 1, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 25, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 24, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 17, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 17, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 16, 2018 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jan 11, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |